Drug Trial Radar · NCT06874621
VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
52
Planned (sponsor's estimate)
Start
Mar 3, 2025
Primary completion
Oct 13, 2026
Study completion May 2027
Sponsor
- Lead sponsor
- Voyager TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to be conducted in participants with early Alzheimer's Disease to test VY7523, a new drug being researched for treatment of Alzheimer's Disease. This study will look at how safe the drug is and how it works in the brain. It was first tested in normal, healthy participants who volunteered to participate. The study will look at three different dose levels, starting with the lowest dose first and moving to higher doses and more participants after safety has been reviewed by doctors and researchers. Some patients will receive drug while others will receive placebo. This will help to better compare how the drug works between participants receiving drug and placebo. The study will last up to 6 months for the lower dose groups and 12 months for the highest dose group.
Conditions
- Alzheimer's Disease (AD)
Interventions
VY7523Drug
VY7523 is a recombinant humanized immunoglobulin gamma 4 (IgG4) monoclonal antibody targeting human pathological tau
Placebo ComparatorDrug
Matching placebo to VY7523
Primary outcomes
What the sponsor says the trial is designed to measure.
- Characterization of the safety and tolerability of VY7523 in participants with early ADTime frame: Cohorts 1 and 2: up to 6 months Cohort 3: up to 12 months
Locations
23 sites in 2 countries. Site status is shown where the registry gives one.
VYGR Site 840018
Los Angeles, California
VYGR Site 840016
Orange, California
VYGR Site 840022
San Francisco, California
VYGR Site 840008
Stamford, Connecticut
VYGR Site 840005
Delray Beach, Florida
VYGR Site 840021
Fort Myers, Florida
VYGR Site 840010
Lady Lake, Florida
VYGR Site 840015
Miami, Florida
VYGR Site 840014
Miami, Florida
VYGR Site 840024
Miami, Florida
VYGR Site 840006
Orlando, Florida
VYGR Site 840003
Stuart, Florida
VYGR Site 840004
The Villages, Florida
VYGR Site 840002
Wellington, Florida
VYGR Site 840020
Winter Park, Florida
VYGR Site 840007
Decatur, Georgia
VYGR Site 840012
Toms River, New Jersey
VYGR Site 840009
Matthews, North Carolina
VYGR Site 840011
Plymouth Meeting, Pennsylvania
VYGR Site 124002
Ottawa, Ontario, Canada
VYGR Site 124001
Toronto, Ontario, Canada
VYGR Site 124003
Montreal, Quebec, Canada
VYGR Site 124004
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.